Loading
A phase 1/2 trial of Cisplatin and Carboplatin in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07466160 by Mabwell (Shanghai) Bioscience Co., Ltd., with 280 participants planned, started 2026-02-11 and due to reach its primary completion in 2027-12-31. Interventions recorded: 7MW3711, JS207, Cisplatin and Carboplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mabwell (Shanghai) Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Cisplatin, Carboplatin and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/